Adherence to long-term use of renin-angiotensin II-aldosterone system inhibitors in children with chronic kidney disease

Table 3 Estimated odds ratios for being associated with medication adherence to RASI chronic therapy

	OR	95% CI		P value
Age at index date, years^a
< 4	1
5–8	0.65	(0.30	1.43)	0.288
9–12	0.38	(0.17	0.82)	0.014
13–17	0.45	(0.22	0.93)	0.031
≥ 18	0.34	(0.16	0.72)	0.005
Male gender	0.68	(0.49	0.94)	0.018
Comorbid conditions
Proteinuria	1.93	(1.18	3.17)	0.010
Anemia	1.76	(1.20	2.58)	0.004
HTN-related	0.32	(0.12	0.86)	0.023
Mineral bone disorders	1.06	(0.60	1.88)	0.839
Diabetes	0.92	(0.48	1.75)	0.790
Hyperlipidemia	1.09	(0.75	1.59)	0.656
Number of ATCs group (initial < 6 months)	1.31	(0.42	4.08)	0.641
Time to RASI chronic therapy	1.12	(1.06	1.19)	<.001
CKD diagnosis
CAKUT	1
Glomerular diagnosis	1.19	(0.59	2.39)	0.626
Others	0.70	(0.33	1.48)	0.351
≥ 2 types of diagnosis	0.64	(0.29	1.42)	0.278

^aThe odd ratio was 0.81 per 3-year increase (95%CI, 0.70–0.94; p = 0.006) in the same regression model; ATC: Anatomical Therapeutic Chemical (ATC) classification coding system (Additional file 1: Table S2)

ISSN: 1471-2431